The Creoptix® WAVEsystem combines crude sample robustness, high sensitivity, and sophisticated software, to create a novel optical biosensor platform for real-time label-free binding kinetics. Engineered around innovative microfluidics and the Grating-Coupled Interferometry (GCI) technology, novel data from difficult samples is now possible for unsurpassed insight.
Together with a temperature-controlled autosampler that can handle 2x 48-vial racks, 96- or 384-well plates or combinations thereof, the WAVE offers the sensitivity to work with low immobilization levels and large ligand-to-analyte molecular weight (MW) ratios.
GCI differs from SPR in how the refractive index change is readout. In SPR, the surface plasmon is quickly attenuated and can pick up signals only from a few interactions. In GCI, each photon travels through the whole waveguide, and hence can pick up the signals from much more interactions, resulting in an intrinsically higher sensitivity.
In addition, the waveguide’s evanescent field penetrates less into the bulk, minimizing disturbances caused by bulk refractive index changes. Refractive index changes at the sensor surface are measured as time-dependent phase-shift signals. This allows for superior high signal-to-noise ratios, measurement of kinetics (ka, kd) and affinity (KD) from low pM to low mM, from signals below 1 pg/mm2 (equivalent to <1RU), for higher sensitivity and confident
kinetic analysis.
For more information, visit:
https://www.malvernpanalytical.com/en/assets/LAY_Brochure_A4_WAVEsystem_2022_update_tcm50-96078.pdf